Please use this identifier to cite or link to this item: https://hdl.handle.net/10321/4645
DC FieldValueLanguage
dc.contributor.authorVenugopala, Katharigatta N.en_US
dc.date.accessioned2023-02-15T09:47:30Z-
dc.date.available2023-02-15T09:47:30Z-
dc.date.issued2022-
dc.identifier.citationVenugopala, K.N. 2022. Targeting the DNA damage response machinery for lung cancer treatment. Pharmaceuticals. 15(12): 1475-1475. doi:10.3390/ph15121475en_US
dc.identifier.issn1424-8247 (Online)-
dc.identifier.urihttps://hdl.handle.net/10321/4645-
dc.description.abstractLung cancer is considered the most commonly diagnosed cancer and one of the leading causes of death globally. Despite the responses from small-cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) patients to conventional chemo- and radiotherapies, the current outcomes are not satisfactory. Recently, novel advances in DNA sequencing technologies have started to take off which have provided promising tools for studying different tumors for systematic mutation discovery. To date, a limited number of DDR inhibition trials have been conducted for the treatment of SCLC and NSCLC patients. However, strategies to test different DDR inhibitor combinations or to target multiple pathways are yet to be explored. With the various biomarkers that have either been recently discovered or are the subject of ongoing investigations, it is hoped that future trials would be designed to allow for studying targeted treatments in a biomarker-enriched population, which is defensible for the improvement of prognosis for SCLC and NSCLC patients. This review article sheds light on the different DNA repair pathways and some of the inhibitors targeting the proteins involved in the DNA damage response (DDR) machinery, such as ataxia telangiectasia and Rad3-related protein (ATR), DNA-dependent protein kinase (DNA-PK), and poly-ADP-ribose polymerase (PARP). In addition, the current status of DDR inhibitors in clinical settings and future perspectives are discussed.</jats:p>en_US
dc.format.extent22 pen_US
dc.language.isoenen_US
dc.publisherMDPI AGen_US
dc.relation.ispartofPharmaceuticals; Vol. 15, Issue 12en_US
dc.subject1115 Pharmacology and Pharmaceutical Sciencesen_US
dc.subjectDDRen_US
dc.subjectHomologous recombination (HR)en_US
dc.subjectNHEJen_US
dc.subjectBERen_US
dc.subjectNERen_US
dc.subjectATMien_US
dc.subjectDNA-PKien_US
dc.subjectPARPien_US
dc.titleTargeting the DNA damage response machinery for lung cancer treatmenten_US
dc.typeArticleen_US
dc.date.updated2022-11-29T16:59:11Z-
dc.identifier.doi10.3390/ph15121475-
local.sdgSDG03-
item.languageiso639-1en-
item.openairetypeArticle-
item.cerifentitytypePublications-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextWith Fulltext-
item.grantfulltextopen-
Appears in Collections:Research Publications (Applied Sciences)
Files in This Item:
File Description SizeFormat
Venugopala_2022.pdfArticle1.45 MBAdobe PDFView/Open
Pharmaceuticals Copyright Clearance.docxCopyright Clearance179.25 kBMicrosoft Word XMLView/Open
Show simple item record

Page view(s)

248
checked on Dec 22, 2024

Download(s)

79
checked on Dec 22, 2024

Google ScholarTM

Check

Altmetric

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.